Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease

OBJECTIVE: The mainstay of treatment for patients with malignant pleural disease is fluid drainage and systemic therapy. A tumor-specific oncolytic virus or T-cell–activating interleukin-2 immunotherapy may provide an opportunity for local control. We previously developed a vaccinia virus–expressing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekeke, Chigozirim N., Russell, Kira L., Murthy, Pranav, Guo, Zong Sheng, Soloff, Adam C., Weber, Daniel, Pan, Wenjing, Lotze, Michael T., Dhupar, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594625/
https://www.ncbi.nlm.nih.gov/pubmed/33485667
http://dx.doi.org/10.1016/j.jtcvs.2020.11.160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594625/
https://www.ncbi.nlm.nih.gov/pubmed/33485667
http://dx.doi.org/10.1016/j.jtcvs.2020.11.160

Ejemplares similares